Anand V Kulkarni, Kumaraswamy P, Balachandran Menon, Anuradha Sekaran, Anuhya Rambhatl, Sowmya Iyengar, Manasa Alla, Shantan Venishetty, Sumana Kolar Ramachandra, Premkumar G V, Mithun Sharma, P N Rao, Duvvur Nageshwar Reddy, Amit G Singal
BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is generally diagnosed at an advanced stage, which limits curative treatment options for these patients. Locoregional therapy (LRT) is the standard approach to bridge and downstage unresectable HCC (uHCC) for liver transplantation (LT). Atezolizumab-bevacizumab (atezo-bev) can induce objective responses in nearly one-third of patients; however, the role and outcomes of downstaging using atezobev remains unknown. METHODS: In this retrospective single-center study, we included consecutive patients between November 2020 and August 2023, who received atezo-bev with or without LRT and were subsequently considered for resection/LT after downstaging...
May 27, 2024: Journal of liver cancer